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Abstract 
We recently reported that activation of Trop-2 through its cleavage at R87-T88 by ADAM10 underlies Trop-2–driven progression 
of colon cancer. However, the mechanism of action and pathological impact of Trop-2 in metastatic diffusion remain unexplored. 
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Metastatic disease is the dominant cause of death in cancer patients, and
is the greatest hurdle for cancer cure. Hundreds of proteins/genes have been
linked to the metastatic phenotype [1] . However, neither proteomic analysis
nor large-scale genome sequencing [2] succeeded in identifying reproducible
markers of tumor aggressiveness and metastasis in cancer patients. 
Metastasis-associated genes include not only drivers of the metastatic
phenotype, but also secondary events, together with adaptive,
counterbalancing changes [3] . Thus, to identify candidates with a decisive
role in metastatic diffusion, we looked for genes that were concordantly
dysregulated across multiple cancer metastasis models. This led to the
discovery that TROP2 is a unique upregulated gene in metastatic colon
cancer prototypes. Trop-2 is a tumor and stem cell growth inducer [4-6] .
We and others showed that Trop-2 drives liver colonization of prostate
cancer cells [ 7 , 8 ]. Additional findings showed that Trop-2 expression
associates to increased in vitro migration and invasion of oral squamous
cell and gallbladder carcinoma cell lines [ 9 , 10 ]. Trop-2 was also reported
to be associated to altered expression of markers of epithelial-mesenchymal
transition (EMT) in stomach and breast cancer [ 11 , 12 ]. 
We recently discovered that proteolytic activation of Trop-2 by ADAM10
underlays its capacity to drive colon cancer malignant progression [13] .
However, Trop-2-driven mechanisms of action and activatory pathways
in metastasis remained unknown. We previously showed that Trop-2 is
upregulated upon tumor progression in colon cancer [6] . Here we find that
impairment of the membrane-to-nucleus signaling by removal of the Trop-2
cytoplasmic tail boosted the liver metastasis rate and stimulated colorectal
cancer growth. NGS and targeted gene-expression profiling showed no
increase in EMT transcription factors nor downregulation of the E-cadherin-
encoding CDH1 gene. We found instead that Trop-2 triggered ADAM10
to cleave E-cadherin, leading to release from the scaffolding cytoskeleton,
with disruption of cell-cell junctions, acquisition of invasive capability and
activation of pro-metastatic signaling by β-catenin. 
This Trop-2-driven metastasis program was found to associate to
a significantly worse relapse-free and overall survival of patients with
colorectal cancer, suggesting a pivotal impact on colorectal cancer
progression. Sacituzumab govitecan-hziy is an anti-Trop-2 antibody-SN-38stasis, we identified TROP2 as unique in its up-regulation across 
 wild-type Trop-2 in KM12SM human colon cancer cells increased 
tic growth was further enhanced by a tail-less, activated cytoTrop-2 
g element. In primary tumors and metastases, transcriptome analysis 
r epithelial-to-mesenchymal transition, thus suggesting that the pro- 
s. Trop-2 can tightly interact with ADAM10. Here, Trop-2 bound 
age of E-cadherin intracellular domain. This induced detachment of 
n of invasive capability, and membrane-driven activation of β-catenin 
nt. This Trop-2/E-cadherin/ β-catenin program led to anti-apoptotic 
ival. In patients with colon cancer, activation of this Trop-2–centered 
ival, indicating a major impact on progression to metastatic disease. 
s shown to be active against metastatic breast cancer. Our findings 
 cancer. 
ling networks, Epithelial-mesenchymal transition 
rug conjugate, which was shown to be effective in metastatic breast cancer
14-17] and was granted accelerated FDA approval as Trodelvy, for use in the
linics. Our findings support an indication for Trop-2-targeting therapies in
etastatic colon cancer. 
aterials and methods 
ells 
The KM12C, KM12SM and KM12L4A human colon carcinoma cell 
ines were obtained from I. J. Fidler, M. D. Anderson Cancer Center. The
M12SM and KM12L4A were derived from the non-metastatic KM12C, 
y in vivo selection for acquisition of metastatic ability [18] . The HCT116
nd HCT116U5.5 human colon carcinoma cell lines [19] were obtained
rom Roche Diagnostics GmbH (Penzberg, Germany). The HCT116U5.5 
lone was derived from the non-metastatic HCT116, by in vivo selection
or acquisition of metastatic ability [19] . Trop-2 low and Trop-2high
ubpopulations were derived from the parental HT29 colon cancer cell line
y fluorescence-activated cell sorting. Frozen master stocks were prepared for
ach cell line within the first two months from receipt. Experiments were
erformed on cells that had been resuscitated from master stocks and passaged
or no more than 6 months. Cell cultures were periodically checked for
bsence of mycoplasma contamination by PCR analyses and DAPI staining.
he IGROV-1, HT29, HCT116 and KM12 cells were maintained in RPMI
640 medium with 10% or 20% FBS respectively, sodium pyruvate, non-
ssential amino acids, L-glutamine and vitamins (Invitrogen). Murine MTE 
-14 cells [13] were grown in DMEM with 10% FBS. Lipofectamine 2000 or
TX (Invitrogen) were used for DNA transfection. Stable transfectants were
elected with G-418 and enriched for expression as described [6] . 
oimmunoprecipitation and Western blotting 
Coimmunoprecipitation was performed as described [7] . Cell lysates and
oimmunoprecipitates were analyzed as previously described [20] . Blots were
ncubated with relevant primary antibodies (as detailed in Supplementary 
ethods) in Tris-buffered saline and 5% non-fat dry milk. Hybridized
lters were washed in TBS, 0.1% Tween-20. Antibody binding was revealed
y chemiluminescence, using horseradish-peroxidase-conjugated anti-mouse 
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(#401215; Calbiochem), anti-rabbit (sc-2004; Santa Cruz Biotechnology) or
anti-goat (sc-2020; Santa Cruz Biotechnology) pAbs. Cleavage of E-cadherin
was assessed by comparing the signals from the antibodies recognizing the
extracellular and intracellular domains of human E-cadherin. Ponceau red
staining was routinely used as control of protein loading [21] . Signal intensity
was quantified with ImageJ 1.47, using as reference a Kodak gray-scale
standards power curve. 
Cell aggregation 
Cells at 70-90% confluence were detached from tissue culture plates
and seeded in low-attachment plates to minimize interference by substrate
binding [22] . Cell aggregation was assessed after 1h and 24h incubation at
37 °C. Aggregates were quantified by image analysis. 
Invasion assay 
Inverse matrigel invasion assay was carried out as described in [23] . Briefly,
100 μl of a matrigel/serum-free medium mixture (1:1) was pipetted into
Transwell inserts in a 24-well tissue culture plate and incubated for 30 min
at 37 °C for settling. Then, the Transwell inserts were inverted and 100 μl of
cell suspension (containing 10,000 cells) was pipetted onto the filter. Inverted
plates were incubated for 4h to allow for cell attachment. The plate was then
turned right-side-up and each Transwell insert placed in a well containing
serum-free medium. Complete medium was gently pipetted on top of the
set matrigel and incubated for 5 d at 37 °C. Transwell inserts were placed in
fresh 24-well dishes containing 1 ml of 4 μM Calcein AM stain solution.
Additional 300 μl of Calcein AM solution was pipetted on top of each filter.
After 1h of incubation at 37 °C, cells were imaged by confocal microscopy
with a 20x objective with optical Z-sections scanned at 15- μm intervals
moving up from the underside of the filter into the matrigel. 
β-catenin reporter assays 
KM12C and KM12SM cells were co-transfected with the β-catenin
reporter pTOPFLASH-EGFP (a kind gift from Prof. Rolf Kemler) and
plasmids encoding for wtTrop-2, cytoTrop-2 or with control empty vectors.
At 48 hours after transfection cells were detached and stained with the T16
anti-Trop-2 mAb conjugated with Alexa-633 for 20 min at 4 °C. GFP and
Trop-2 expression were analyzed by flow cytometry. 
Flow cytometry 
Cell analyses and sorts were performed as described [24] (FACSCalibur,
FACSCanto II, FACSAria III flow cytometers/cell sorters BD Biosciences).
Subtraction of cell autofluorescence and displacement in the red channel were
performed for Alexa488-stained cells [6] . 
Pre-clinical models 
KM12 cell transfectants were injected in the spleen of 8-week old female
athymic Crl:CD1-Foxn1 nu mice (Charles River Laboratories). After 4 weeks
mice were euthanized; tumor growth and diffusion to the liver or other organs
were determined. All autoptic samples underwent microscopy histopathology
analysis to detect minimal primary tumor or metastatic burdens. 
Pre-clinical protocols were approved by the Italian Ministry of
Health (Prog. 19, 2006) and by the Interuniversity Animal Research
Ethics Committee (CEISA) of Chieti-Pescara and Teramo Universities
(Prot.26/2011/CEISA/PROG/16). atients 
IHC analysis for Trop-2 expression was performed on normal colon 
ucosa, colon cancer and colon cancer metastases. Trios of normal tissue, 
rimary tumor, and metastasis from individual patients bearing breast, uterus, 
vary, or colon cancers were analyzed by cDNA RT-PCR/dot blot assay. 
aplan-Meier curves and Cox proportional hazard models were utilized to 
uantify impact on relapse-free and overall survival of cancer patients. 
Studies on human tumor samples were approved by the Italian Ministry 
f Health (RicOncol RF-EMR-2006-361866, 2006) and by the ethical 
ommittee of the University of Regensburg (Germany). 
tatistical analyses 
Normality of distribution of assay values was verified ( www.graphpad. 
om ). Student t-test was utilized for comparison between protein level means 
etween experimental groups. Two-tailed Fisher exact test was utilized to 
ompare tumor take rates and metastasis frequency. Spleen primary tumors 
nd liver metastasis parameter counts (pseudo-glandular differentiation, 
itotic figures and apoptotic bodies) were displayed graphically through 
oxplot representations. Equality of distributions was tested by the Wilcoxon 
ank sum test, adjusting the significance level for multiple comparisons by the 
onferroni correction (0.05/2). 
ESULTS 
ranscriptome profiling of metastatic colon cancer cells 
To identify drivers of metastatic diffusion, we profiled transcriptomes of 
nrelated cancer-metastasis systems, in a quest for concordantly dysregulated 
enes. To date, candidate metastasis genes primarily originated from mouse 
umor models [25] . Hence, we focused on human metastatic cancer systems. 
wo independent human colon cancer metastatic models were analyzed, i.e. 
he non-metastatic HCT116 versus metastatic HCT116U5.5 cells [19] and 
he non-metastatic KM12C versus metastatic KM12SM and KM12L4A cells 
18] . The HCT116U5.5 metastatic clone was derived from lung metastases of 
ubcutaneously (SC) injected HCT116 cells [19] . Metastatic KM12SM and 
M12L4A cells were derived from liver metastases of KM12C cells injected 
n the mouse spleen [18] . DNA microarray analysis for the expression of
2652 genes in the HCT116 and KM12 metastatic models, identified 70 and 
59 differentially expressed genes, respectively (Supplementary Results , Table 
1). The intersection of these independent datasets showed predominant, 
utually-exclusive expression changes ( Fig. 1 A ), indicating widely divergent 
ranscriptomic scenarios in the two colon cancer models. Only two genes, 
ROP2/TACSTD2 and VIMENTIN , were upregulated in both systems 
 Fig. 1 A, Table S1), first suggesting that pro-metastatic programs may only
equire few decisive determinants. mRNA findings were validated by RT-PCR 
 Fig. 1 B ). Differential expression of the encoded proteins was validated by
estern blotting ( Fig. 1 B ), immunofluorescence confocal microscopy and 
mmunohistochemistry (IHC) ( Fig. 1 C ). 
he role of Trop-2 in metastatic diffusion 
Trop-2 proteolytic cleavage by ADAM10 at R87-T88 is required for 
ctivation as a driver of primary tumor growth and malignant progression 
13] , while a two-step A187-V188 and G285-V286 intramembrane 
roteolysis releases the Trop-2 intracellular tail, which then co-translocates 
ith ß-catenin to the nucleus [4] . To dissect the contribution of Trop-
 nuclear signaling to colon cancer metastasis we designed a membrane- 
nchored mutant of Trop-2 devoid of the cytoplasmic tail ( cytoTrop-2). 
tTrop-2 and cytoTrop-2 KM12SM cells were selected by flow cytometry 
or membrane expression levels comparable to those found in human cancer 
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Fig. 1. Transcriptome profiling of metastatic colon cancer cells. ( A ) Transcriptome profiling of metastatic colon cancer cells: HCT116U5.5 vs HCT116 (HCT 
column) and KM12L4A (A) or KM12SM (B) vs KM12C (KM12 columns). The profiles of the two independent colon cancer metastatic models showed 
largely mutually exclusive expression changes, indicating widely divergent transcriptomic scenarios. Pseudo-color-coded change factors (CF), according to the 
scale bar (green, increased expression in metastatic cells; red, decreased expression; white, no change). Genes are sorted by descending CF values in HCT116 
cells. Yellow highlight: only two genes, TROP2/TACSTD2 and VIMENTIN , were upregulated in both systems. ( B ) Expression levels of TROP2 mRNA in 
KM12C and HCT116 versus KM12SM, KM12L4A or HCT116-U5.5 colon cancer cells. DNA microarray and Northern blot ( left ), and RT-PCR ( upper 
right ) analyses, with ACTB and 28S as loading controls. Western blot analysis ( lower right ) for corresponding Trop-2 protein expression were also performed, 
with β-actin as loading controls. ( C ) IHC and immunofluorescence assessment of Trop-2 expression in KM12SM and HCT116 U5.5 versus HCT116 colon 





































(Fig. S1) [6] . KM12SM transfectants were then assayed for capacity to
metastasize to the liver upon injection in immunosuppressed mouse spleen
(Figure S1) [18] . wtTrop-2 strikingly increased the metastatic capacity of
KM12SM cells, raising metastasis rates from 45% for control cells to 90%
for wtTrop-2 transfectants ( Fig. 2 A , Table 1 , Table S2 A ). The tail-less
cytoTrop-2 boosted metastatic growth, with metastatic livers reaching up to
four times their normal size at four weeks after tumor injection (3.25 ± 0.64
cm3 versus 0.45 ± 0.18 cm3 for wtTrop-2, P < 0.0001) ( Fig. 2 A , Table 1 ,
Table S2 A ). 
Histopathology analysis showed patterns of tumor growth of parental
KM12SM cells as manifo.ld nodules, with central necrosis and peripheral
fibrous capsule. Residual tumor differentiation capacity was demonstrated
by gland rudiments containing apoptotic bodies in their lumen. This closely
mirrored human colon cancer, where such crypt-like architecture associates
with low cancer grading and good prognosis [26] ( Fig. 2 B , Fig S1 , Table
S2 B ). wtTrop-2-expressing metastases showed much reduced numbers of
differentiated glands (mean ±SD glands/20x field: 0.9 ± 0.97 versus 3.42
± 0.86 in controls, P = 0.0003). Poorly differentiated, smaller crypts were
also reduced in frequency (2.54 ± 2.33 versus 10.58 ± 7.33 in controls, = 0.0026). Thinner peri-metastatic capsule and pseudo-capsule and 
requent mitotic figures (mean ±SD mitotic figures/20 × field 10.98 ± 9.18
ersus 1.58 ± 2.11 in controls, P = 0.0004) were observed ( Figs. 2 B-C , Figure
 1, Table S2 B ). Augmented vascular invasion capacity was also observed
 Fig. 2 B ). Loss of central-nodule apoptosis, and a shift toward smaller and
eripheral necrotic areas, indicated a reduced apoptotic response to oxygen
radients/distance from blood vessels [ 27 , 28 ] ( Figs. 2 B-C, Table S2 B ). 
cytoTrop-2 induced dramatic changes toward invasive growth patterns, 
ith further loss of differentiated glands (0.12 ± 0.32, P < 0.00001 versus
ontrol) and poorly differentiated glands (1.72 ± 1.44, P = 0.0007 versus
ontrol) ( Fig. 2 B , Fig. S 1, Table S2 B ). Frequent mitotic figures were found
5.34 ± 4.39, P = 0.022 versus control) ( Fig. 2 C , Fig. S1 , Table S2 B ). Cancer
ell invasion was detected across layers of hepatocytes or even within pre-
xisting metastatic areas ( Fig. 2 B ), with patterns of invasive growth and little,
f any, pseudo-capsule formation. Haemorrhagic necrosis indicated damage 
o vascular walls. Trop-2-dependent metastases showed diminished apoptotic 
eatures in activated cytoTrop-2 versus parental KM12SM cells (mean ±SD
poptotic bodies/20x field: 6.92 ± 5.36 versus 13.16 ± 12.75, respectively) 
 Fig. 2 C , Fig. S1 , Table S2 B ). 
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Fig. 2. Trop-2 drives metastasis in vivo. ( A ) Primary spleen tumors and metastatic livers from nude mice injected intra-spleen with KM12SM cells transfected 
with vector alone, wtTrop-2 or cytoTrop-2. Representative images are shown, full data analysis is in Table S2A. ( B , top ) Histopathology analysis of spleen 
and liver tumors from KM12SM transfectants. Control KM12SM/vector cells (left), with central necrotic areas (red arrowheads), defined fibrous capsules 
and glandular lumen rudiments with apoptotic bodies ( inset , black arrowheads); KM12SM/wtTrop-2 ( middle ), showing a pleomorphic appearance, numerous 
mitotic figures and lesser necrosis compared with vector-alone (red arrowheads) and instances of endoluminal vascular growth ( bottom panel, inset ); cytoTrop- 
2 induced further loss of differentiation: KM12SM/ cytoTrop-2 (right), showing an invasive growth pattern ( bottom panel, inset ), frequent mitoses and 
peripheral haemorrhagic necrosis. ( B , bottom ) Decreased cell-cell adhesion in liver metastases from KM12SM/ cytoTrop-2 (right) compared to liver metastases 
from KM12SM/vector cells (left) (arrows). Nodular growth borders are indicated by arrowheads. A representative image of the extent of pseudoglandular 
differentiation in parental (vector), wtTrop-2 (wtT2), cytoTrop-2 ( cT2) cells is shown in the central panel, with data analysis as distribution boxplots of 
small and large gland-like structures shown below. ( C) Spleen tumors and liver metastases from control parental KM12SM, wtTrop-2 and cytoTrop-2 were 
scored for occurrence of apoptotic bodies ( top ) and mitotic figures ( bottom ) (arrowheads). Representative images are shown on the left, with data analysis as 
distribution boxplots shown on the right. Tissue sections were stained with haematoxylin and eosin. Size bars = 50 μm. Individual counts for psuedoglandular 
structures, apoptotic bodies and mitotic counts were obtained per independent 20x optical field and are listed in Table S2 B . Statistical analysis was conducted 
as in Material and Methods. Vector: n = 6; wtTrop-2: n = 25; cytoTrop-2: n = 35. 
Table 1 
In vivo metastatic capacity of colon cancer cells expressing Trop-2. 
% spleen a size (cm 3 ) % liver b size (cm 3 ) 
vector 64.9 ± 8.7 0.11 ± 0.04 45.8 ± 14.8 0.50 ± 0.21 
wtTrop-2 69.0 ± 10.6 0.09 ± 0.03 90.0 ± 12.0 c 0.45 ± 0.18 
cytoTrop-2 100.0 ± 0 d 0.37 ± 0.23 e 76.9 ± 11.7 3.25 ± 0.64 f 
vector: n = 37; wtTrop-2: n = 31; cytoTrop-2: n = 13. 
Data were from 3 to 9 experiments per group. Values are expressed as 
mean ±SEM. Bold: statistical significance or trend. 
a primary tumors take rates (percentage of injected cases). 
b percent incidence of liver metastases. 
c Fisher’s exact test: P = 0.0114 versus vector. 
d Fisher’s exact test: P = 0.0382 versus wtTrop-2. 
e trend. 
f Student’s t test: P < 0.0 0 01 versus wtTrop-2. 












































































































o  Trop-2 prompted cancer cell rounding and diminished cell-cell adhesion
in primary tumors and metastases ( Fig. 2 B, bottom panels; Fig. S 1 ). 
Profiling of metastatic transcriptomes 
NGS transcriptome analysis was conducted on independent KM12SM
colon primary tumors and metastases (Figure S1), to detect Trop-2-
driven, differential expression of pro-metastatic determinants (Fig. S2).
Compound EST analysis showed high intra-group R correlation coefficients,
with robust segregation of parental cells, wtTrop-2 and cytoTrop-2,
primary cancer and metastasis expression profiles. Sequence alignment over
Mus musculus or Homo sapiens reference genomes formally discriminated
transcripts of human cancer origin versus murine stromal components
(Table S 3 ). 
Human EST profiles of primary tumors showed invariant expression of
87.1% of 15782 transcripts between wtTrop-2-expressing versus parental
cells. On the other hand, only 19.2% mRNA expression patterns overlapped
in wtTrop-2 and control liver metastases, indicating that Trop-2 induces a
distinct pro-metastatic program (Fig. S2 A , Table S3). Wide modulation of
the E-cadherin/ß-catenin/TCF-LEF and Wnt/Frizzled/DVL1/APC/ß-
catenin pathway components was found, suggesting these to be
drivers of Trop-2-induced metastasis. Modulated downstream targets
included apoptosis regulators, such as PI3K/Akt [27] , NFkB [28] ,
p53 [29] , cFOS, caspases 3 and 9, JAK/STAT1-3 and Cyclin D1 [28]
(Fig. S2 B ). 
Canonical EMT models predict progression to a metastatic state through
loss of epithelial differentiation, via transcriptional downregulation of
epithelial determinants, such as E-cadherin [ 1 , 2 , 30-32 ]. Hence, we explored
EMT drivers versus epithelial differentiation markers in Trop-2-driven
metastatic cells (Table S3 H ). Of 203 EMT biomarkers, 129 were transcribed
in the colon cancer cells, 16 were differentially modulated by wtTrop-
2/ cytoTrop-2; 164 biomarkers were expressed in the tumor stroma, 76 of
these were differentially modulated by wtTrop-2 and cytoTrop-2. The EMT
transcription factors TWIST1, TWIST2, ZEB1, ZEB2, SNAI2, KLF8,
PRRX1, GSC, SIX1 and TCF4 were absent from Trop-2-driven colon cancer
cells, SNAI2 was only expressed by the cancer stroma. TFAP2A and TCF3
were downregulated by wtTrop-2 in metastases. (Table S3 H ). Vimentin
was not upregulated in metastatic colon cancer cells, but was induced by
cytoTrop-2 in stromal cells, consistent with a model whereby the metastasis
stroma contributes to global EMT shifts [2] . 
Among epithelial differentiation determinants, MAPK6,
EPCAM/TACSTD1/TROP1 [33] and most keratins were expressed at
comparable levels in primary tumors and metastases. KRT80 , which is
associated with progression of colon cancer, was downregulated by wtTrop-2
in metastases (Table S3 H ). None of the α-integrins, including α6, nor the
β-integrins, among them β1, β3, were significantly modulated in cancer
cells or stroma. Myosins/ β-actin are dynamically co-recruited at the cell
membrane upon cross-linking with anti-Trop-2 antibodies. Consistent
with this, numerous myosin isoforms were differentially modulated in
metastases, whether in stroma (Myo 1a, 1b, 1c, 1f, 1g, H11, L9) or in
cancer cells (Myo5a, 6, 7, 10, HC7B, HC10, HC15, myosin regulatory light
chain - MRLC2). Conserved, high levels of CDH1 mRNA were revealed
in metastases from wtTrop-2 and cytoTrop-2 versus vector-transfected
KM12SM cells as well as in primary tumors across all experimental groups
(Table S3 H ). RT-PCR, FACS and Western blotting analyses also showed
invariant levels of E-cadherin transcript and protein across transfectants and
between control Trop-2-nil/non-metastatic KM12C and Trop-2-low/pro-
metastatic KM12SM cells (Figs. S3 A-B, D ). 
Taken together these data suggested limited impact of Trop-2 on epithelial
differentiation, at variance with previous, more limited analyses [ 11 , 12 ]. rop-2 releases E-cadherin from the β-actin cytoskeleton and activates 
-catenin 
Our findings showed that Trop-2 impacts on the E-cadherin/ß-catenin 
athway in metastasis (Figs. S2 B, Table S3 H ). Evidence of Trop-2-associated
eduction in cell-cell adhesion had been obtained by morphometric analysis
f metastases growing in vivo. Together, these findings suggested a regulatory
unction of Trop-2 on intercellular junctions via alternative mechanisms to
DH1 downregulation. 
Coimmunoprecipitation assays revealed that wtTrop-2 tightly interacts 
ith E-cadherin ( Fig. 3 A ). cytoTrop-2 bound E-cadherin to a lesser extent,
rst suggesting a role of the Trop-2 cytoplasmic tail in macromolecular
ssembly with E-cadherin. We thus hypothesized an antagonistic function of
rop-2 versus E-cadherin/ß-catenin-mediated cell-cell adhesion that would 
ritically contrbute to metastatic diffusion [34] . This was explored in in
itro assays on low cell-attachment substrates. wtTrop-2 and cytoTrop-2 
arkedly diminished KM12SM cell-cell adhesion ( Fig. 3 C ). Distribution
rofiles of wtTrop-2 / cytoTrop-2 cells indicated a highly significant
eduction in aggregates with respect to control cells ( χ2 test P-value
 2.2e −16). A shift of aggregate cluster size, toward smaller cell clusters
nd isolated cells, was correspondingly observed ( Fig. 3 C ). Corresponding
nvasive capability of KM12SM transfectants was assesses by inverse matrigel
nvasion assays [35] . wtTrop-2 expression conferred KM12SM cells the ability
o invade through the matrix, compared with the control vector-only cells.
nvasive ability was maintained by the tail-less cytoTrop-2 mutant ( Fig. 3 B ),
ith no significant difference in the number of invading clusters with respect
o the wt-Trop-2. cytoTrop-2 clusters were smaller than the wt Trop-2 ones
t 5 days from seeding, which could reflect differences in cell growth kinetics
see below). 
We have previousy shown that Trop-2 tightly interacts at the cell
embrane with the ADAM10 metalloproteinase, which in turn leads to
ctivation of Trop-2 via proteolytic cleavage at R87-T88 [13] . ADAM10
as also been shown to be responsible for E-cadherin processing in epithelial
ell monolayers, which regulates cell adhesion and sorting [36] . Hence we
nvestigated whether Trop-2 could drive E-cadherin functional inhibition 
ia ADAM10 proteolysis. Western blot analyses of KM12SM tranfectants 
evealed that Trop-2 induces the release of the E-cadherin 30 kD intracellular
omain ( Fig. 4 A ). To validate this finding we assessed E-cadherin status in the
T29 colon cancer cell line, which displays a bimodal distribution of Trop-2
xpression ( Fig. 4 B ). Western blot analyses of distinct HT29 subpopulations
elected for low versus high levels of Trop-2 expression confirmed stimulation
f E-cadherin cleavage by Trop-2 ( Fig. 4 B ). Downregulation of ADAM10
xpression by a specific inhibitory shRNA abolished E-cadherin proteolysis 
n KM12SM/Trop-2 transfectants ( Fig. 4 C ), thus indicating ADAM10 as
he effector protease of Trop-2-induced E-cadherin shedding. Specificity was 
onfirmed with a second, independent ADAM10 shRNA, which was equally
ffective in inhibiting Ecadherin processing (Fig. S3 E ). 
The E-cadherin/ β-catenin complex requires anchoring to the β- 
ctin cytoskeleton for effective cell-cell adhesion [37] . wtTrop-2 severely
iminished, and cytoTrop-2 essentially abolished, E-cadherin binding to 
he actin cytoskeleton ( Fig. 3 A ). Mechanistic analysis showed binding of
rop-2 to ezrin, indicating this as a requirement for bridging the Trop-2/E-
adherin/ β-catenin complex to the cytoskeleton ( Fig. 4 D ). 
E-cadherin inactivation leads to activation of the β-catenin transcriptional 
ctivity [37] . Such activation requires transit of β-catenin at the cell
embrane, for dephosphorylation at S37/T41 [38] . KM12C, pro- 
etastatic parental KM12SM and KM12SM cells transfected with wtTrop- 
, cytoTrop-2 or control vector were analyzed by confocal microscopy
or β-catenin levels and localization (Figs.S3 C,F-G , Figs. 5 A-B, Table S4 A ).
onsistent with a gradient of metastatic competence, the lowest levels
f nuclear β-catenin were found in the non-metastatic KM12C < pro-
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Fig. 3. Trop-2 drives functional inactivation of E-cadherin ( A ) E-cadherin immunoprecipitates from KM12SM transfectants were analysed by Western blotting 
for β-catenin ( β-cat), Trop-2 and β-actin ( β-act). E-cadherin (E-cad) was also probed as control ( left ). Corresponding cell lysates were also analysed, with Akt 
as protein loading control ( right ). (B) Matrigel invasion by KM12SM vector-alone transfectants compared to KM12SM cells expressing either the wtTrop-2 
or the cytoTrop-2 at 5 days from seeding (left). Representative images of three independent experiments are shown. The arrow indicates the direction of 
invasion through the Matrigel layer. Clusters of invading cells are detected only upon overexpression of Trop-2. The total number of invading clusters was not 
significantly different between wtTrop-2 and cytoTrop-2. The distance of each invading cluster from the matrigel surface along the Z axis was measured; 
average values for each group are showm in the histogram on the right. ( C ) Cell-cell aggregation in KM12SM transfectants, assessed 1 h and 24 h after seeding 
on low-attachment plates. Representative phase-contrast images are shown ( top ). Distribution of cell aggregation states after 1 h from seeding was profiled as 


































metastatic parental KM12SM < wtTrop-2 < cytoTrop-2. Quantitative
image analysis showed progressively higher mean values of nuclear/activated
β-catenin in vector (mean ±SEM 2604 ± 240 SV), wtTrop-2 (mean:
3362 ±283 SV; P < 0.0001 versus control vector) and cytoTrop-2 cells
(mean: 4431 ± 196 SV; P < 0.0001 versus wtTrop-2) (Fig. S3 G, Fig. 5 A-B,
Table S4 A ). This demonstrated that β-catenin signaling activation by Trop-2
in colon cancer does not require clustering with a membrane-released Trop-2
cytoplasmic tail [4] . 
We verified the transcriptional competence of Trop-2-activated β-catenin,
using a β-catenin-RE-GFP reporter ( Figs. 5 B,C ). GFP-expressing/ β-catenin-
responsive KM12C cells were 13%. wtTrop-2 increased the percentage of
GFP-expressing/ β-catenin-responsive KM12C cells to 24%; cytoTrop-
2 led them to 28%. As predicted, Trop-2-positive metastatic KM12SM
showed higher baseline transcriptional values (47%) than non-metastatic
KM12C cells. Overexpression of wtTrop-2 in KM12SM cells led to a further
increase of responsive cells to 54% ( Figs. 5 B,C ). The highest β-catenin-driven
GFP expression was induced by cytoTrop-2 (67% of above-threshold
cells). β-catenin impact on transcription of target genes in vivo was assessed. 
-catenin regulates genes associated with proliferation, differentiation, 
igration and angiogenesis. A set of 277 β-catenin target genes in colorectal 
ancer was retrieved (web.stanford.edu/group/nusselab/cgi-bin/wnt/target _ 
enes ; Gene Expression Omnibus database). This included “direct” targets, 
s defined by the presence of TCF binding sites, and “indirect” targets, 
s obtained from large-scale β-catenin inactivation screening programs. β- 
atenin targets included the proto-oncogenes MYC and CCND1 , as well 
s the genes encoding the basic helix-loop-helix proteins ASCL2 and ITF- 
B [39] . This dataset was interrogated in primary tumors and metastases. 
ost remarkably, essentially no impact of Trop-2 on β-catenin target 
enes was revealed in primary tumors. Further, β-catenin was found to be 
ownregulated in control, parental KM12SM metastases, with further loss 
f transcription of β-catenin targets. Massive changes were, on the other 
and, revealed in β-catenin target genes in wtTrop-2 metastases (89 target 
ranscripts, 61 genes overall) (Table S4 B ). Notably, control and wtTrop-2- 
odulated mRNAs showed no overlap, indicating that Trop-2 triggered a 
istinct control mechanism of metastatic diffusion. The vast majority (50) of 
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Fig. 4. Trop-2 induces E-cadherin cleavage by ADAM10 ( A ) Western blot analysis of KM12SM/Trop-2 and vector-only transfectants with antibodies against 
the E-cadherin N-terminal extracellular domain ( top ) or C-terminal cytoplasmic tail ( bottom ). Molecular weight markers are indicated on the right. Red 
arrowhead: cleaved E-cadherin 80 kD extracellular domain and 30 kD cytoplasmic domain. Ponceau red staining is shown as protein loading control. (B) 
HT29 colon camcer cell subpopulations were selected from the parental cell line by flow cytometry for low/nihl or high expression of Trop-2 ( top ) and analysed 
for E-cadherin cleavage by Western blotting as above on full length gels ( bottom ). Uncleaved E-cadherin provide loading control. ( C ) KM12SM/Trop-2 cells 
were infected with a lentiviral shRNA targeting the ADAM10 transcript (ADAM10-sh1) or with a scramble shRNA (scr-sh) as control. ADAM10 levels ( top ) 
and E-cadherin cleavage ( middle, bottom ) were revealed by Western blotting as above. Ponceau red staining is shown as protein loading control. ( D ) Trop-2 
immunoprecipitates from KM12SM transfectants were analysed by Western blotting for ezrin ( top ). Ezrin levels in corresponding whole lysates are shown 































modulated genes was shared between wtTrop-2 and cytoTrop-2. Marked
increased transcription was induced by cytoTrop-2 versus wtTrop-2 in most
cases (65/71 genes), consistent with the activated nature of cytoTrop-2 and
the aggressiveness of its induced metastases. 
The Trop-2/E-cadherin/ β-catenin pro-metastatic module in vivo 
The Trop-2/E-cadherin/ β-catenin pro-metastatic module was validated
in colon cancer metastatic xenotransplants. E-cadherin and β-catenin levels
were assessed by IHC analysis of matched primary tumor/metastasis pairs.
wtTrop-2 KM12SM colon cancer cells showed higher levels of E-cadherin
than control, parental cells. Further increase in levels of expression and
recruitment to the cell membrane were detected in cytoTrop-2 cells (Fig.
S4 A ). Subgroup analyses of primary spleen tumors showed that 45% of
controls were devoid of E-cadherin, and only 20% of cases reached high levels
of expression. On the other hand, 70% of wtTrop-2 tumors expressed E-
Cadherin, 20% of cases reaching high levels. No cytoTrop-2 tumors were
devoid of E-cadherin, and almost 60% of cases reached high expression levels
(Fig. S4 B ). In parallel assays, the lowest levels of β-catenin were found in parental
M12SM primary tumors. β-catenin expression increased in liver metastases 
Fig. S4 A ). cytoTrop-2 xenotransplants showed a vast increase of β-catenin
xpressing cells versus control tumors. Correspondingly high β-catenin 
xpression was maintained in matched metastases (Fig. S4 A ). Subgroup
nalysis for expression of β-catenin showed that 90% of control tumors did
ot express the protein, and none reached high levels of expression. On the
ther hand, 10% of wtTrop-2 and 60% of cytoTrop-2 tumors expressed
igh levels of β-catenin (Fig. S4 B ). 
rop-2 metastatic signalosome dissection 
Metastatic diffusion requires resistance to apoptosis, enhanced migration 
nd invasiveness. We modelled the contribution of these mechanisms to the
rop-2-driven metastatic process through global, multi-platform proteomic 
nalyses (Fig. S5, Table S5) and in vitro functional assays (Fig. S6). 
Proteomic analysis of wtTrop-2 and cytoTrop-2 metastatic cells showed 
odulation of RTK signaling, including Erb-B2, PDGFR α, FAK, the FAK-
elated kinase Pyk2 and PKCs, with Src/FAK-dependent JNK activation 
Figure S5, Table S5). wtTrop-2 induced activatory phosphorylation of 
906 Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer E. Guerra et al. Neoplasia Vol. 23, 
No. xxx 2021 
Fig. 5. β-catenin release and activation by Trop-2. Activation of β-catenin transcriptional activity requires transit at the cell membrane and transport to 
the nucleus. Levels and localization of β-catenin were analyzed in KM12C, KM12SM cells transfected with wtTrop-2, cytoTrop-2 or control vector. ( A ) 
Confocal microscopy analysis of active unphosphorylated β-catenin in KM12SM transfectants. Active β-catenin colocalization with E-cadherin at the cell 
membrane ( left ). Nuclear localization (arrowheads): nuclei were identified by counterstaining with DRAQ5 (blue pseudo-color) ( middle ). Co-staining with 
Trop-2 ( left ) ( B ) Histogram plots of active β-catenin in the nuclei of KM12SM transfectants (see Table S5 for the full dataset) ( top ). Histogram plots of 
GFP-positive/ β-catenin-responsive cells in KM12C non-metastatic and KM12SM metastatic transfectants; subgroup percent values are indicated. ( C ) Flow 
cytometry analysis of GFP expression in KM12SM cells co-transfected with the pTOPFLASH-EGFP β-catenin-reporter and the empty vector ( top ) or the 
expression vector for wtTrop-2 ( tmiddle ) or cytoTrop-2 ( bottom ). GFP average fluorescence intensity (FI) is indicated as normalized for Trop-2 transfection 
efficiency. 


















































































































Akt at T308 [27] . This was further increased ( + 80%) by the cyto
Trop-2 mutant, with Akt-mediated inactivating phosphorylation of Raf-1
(S259) and GSK3 α/ β (Ser21/Ser9) [27] (Fig. S5 A,B , Table S5). Trop-2
induced Akt-mediated activation of c-Jun [40] (Table S5). This paralleled
claudin-dependent, Akt-driven modulation of the FoxO1/TCF-4/ β-catenin
transcriptional repressor complex for cell-cell junction assembly [41] .
Inactivation/downregulation of Rb contributes to metastatic spreading [42] .
Consistent with this, we found reduced levels of Rb in KM12SM cells upon
expression of wtTrop-2, and these paralleled activating phosphorylation of
PKC ε at S729 [43] ; Rb levels were further reduced by the cyto mutant
(Figs. S5 A,B ). Cyclin D1/cdk4 complexes trigger Rb phosphorylation at
S807/811 and prevent binding to E2F-1 [44] . Consistent with a model of
Trop-2-driven Rb inactivation, these sites were found hyperphosphorylated
in KM12SM/Trop-2 ( + 221.2%) (Table S5). 
A large fraction of the 170 proteomic changes which were detected in the
Trop-2 signalosome were found to be induced by both wt and cytoTrop-
2 (Fig. S5 C , Table S5 D ). In 23 instances, concordant variations of absolute
amounts and/or extent of activatory phosphorylation of signaling proteins
were recorded, suggesting these to be core Trop-2-dependent signaling
events (Table S5 D ). cytoTrop-2 downregulated absolute amounts and
phosphorylation/activation of the p38/MAPK14 cell death inducers and
downstream effectors IRAK-1, IRAK-3, TRADD, JAK3, STAT-1 (S727),
JAK2 (Y1007-1008) (Table S5). These findings, and the activation of
the Ras/Raf/MEK, PTEN/Akt/GSK3, p38/MAPK14, and PKC ε (S729)
pathways, indicated impact of Trop-2 on pro-survival signaling [1] . 
A pro-survival role of Trop-2 was validated in in vitro functional assays
in a range of Trop-2-responsive cell systems (KM12SM colon cancer cells,
IGROV-1 ovarian cancer cells, MTE4-14 murine thymic cells; Figs. 6 A-
B ) [ 6 , 13 ]. Serum-deprived IGROV-1 and KM12SM/Trop-2 transfectants
reached much higher saturation values and survived markedly longer than
vector-alone control cells (Figs. S6 A-B ). Activated cytoTrop-2 had a larger
impact than wtTrop-2 on cell culture saturation density and survival over
time (Fig. S6 A ). Of note, cytoTrop-2 induced slower growth of transfected
cells than wtTrop-2 up to 48 hours from seeding, supporting a model of
a distinct control of Trop-2 on cell growth versus survival [28] , as well as
versus invasion ( Fig. 3 B ). This was validated in 3D models of metastatic colon
cancer, as HCT116 cell spheroids [45] were not appreciably induced to grow
by wtTrop-2 (Fig. S6 C ). 
Increased cell migration underlie metastatic spreading [ 1 , 31 ]. In wound-
healing assays, wtTrop-2 induced effective wound closing (22% of wound
area coverage at 6 h versus 14% in parental cells; 78% versus 17% at 24 h
in parental cells). cytoTrop-2 further increased cell migration ability, with
complete wound closure at 24 h after seeding (Fig. S6 D ). 
Selective pressure for Trop-2 expression in metastatic disease 
Our findings predicted a critical impact of the Trop-2-driven pro-
metastatic program in colon cancer. This was assessed in multiple case series
of cancer patients. Proof of principle IHC analysis for protein expression
showed progressive induction of Trop-2 from the Trop-2-negative normal
colon mucosa, to colon cancer, to metastases, which showed strikingly high
expression of Trop-2 (Fig. S7 C ). Trios of normal tissue, primary tumor,
and metastasis from individual patients bearing colon, cancer were then
analyzed by cDNA dot blot analysis. This showed overexpression of TROP2
in metastasis in 73% of cases (n = 11) (Fig. S7 A , Table S6 A ). Such selective
pressure for higher expression of TROP2 in metastasis, supported a driving
role of TROP2 in metastatic diffusion. This applied also to organs and tissues
where normal cells do not express TROP2 , indicating reshaping of gene
expression control networks according to a common malignant progression
trajectory. 
We verified the relevance of such findings in independent cancer patient
case series. Analysis of 9 colon cancers and matching metastases indicatedpregulation of TROP2 in metastatic lesions (Fig. S7 B ). Such impact of a
lobal TROP2 overexpression in metastases was challenged by IHC analysis
f a validation case-series of colon normal tissues, primary cancers and
atching metastases (n = 48) (Table S6 A-B ). This revealed that Trop-2
as overexpressed in metastases (Fig. S7 D, Table S6 A-B ), with probability
stimates (95% confidence intervals) for higher fractions of metastatic IHC-
ositive cells than in primary tumors of 88% (CI = 78-97%) of colon
arcinomas. 
rop-2 is a predictor of survival in colon cancer patients 
We thus went on for assessing Trop-2 impact on colon cancer malignant
rogression and disease outcome. This was assessed in two independent colon
ancer case series. A first patient population (n = 80) was examined, with
edian age of 72 years (range, 30-88) and heterogeneous tumor grading.
valuable dissected samples indicated lymph-node metastasis at diagnosis in 
2 patients, whereas 37 patients were metastasis-free. IHC analysis ( Fig. 6 A)
howed expression of the Trop-2 protein in 65/80 (81.2%) cases. The
raction of Trop-2 expressing cells in the positive cases was up to 100%,
ith a mean ± S.E. of 41.6% ± 4.0. Among the 80 tumors, 40 (50.0%)
xhibited Trop-2 overexpression (Trop-2 high ). Trop-2 high was significantly 
ssociated with metastasis to lymph-nodes ( P = 0.047) (Table S6 C ). No
ignificant association was detected between Trop-2 expression and other 
linicopathologic variables (age, sex, degree of tumor differentiation, tumor 
taging, tumor invasion). 
To quantify the impact of Trop-2 expression on patient survival, a second
eries of 53 colon cancer patients was surveyed for an extended follow-up time
 ≈400 months). ROC analysis was applied to compute a Trop-2 positivity
hreshold according to the 0, 1-criterion. The optimal cut-off parameter for
rop-2 positive expression was 88%. Kaplan-Meier curves showed above- 
hreshold expression as significantly associated with poor OS, with death
f 57.1% of patients. Only 37.8% of Trop-2 low cases encountered death (
 = 0.020) ( Fig. 6 B , Table S6C). 
We then went on to assess the impact of coordinate expression of Trop-2
 TROP2, TACSTD2 ) , E-cadherin ( CDH1 ), β-catenin ( CTNNB1 ) on disease
utcome and patient survival. Next-generation sequencing analysis of tumor 
ranscriptomes of 597 cases of colon cancer in the TCGA dataset ( www.
roteinatlas.org) confirmed a negative prognostic impact of TROP2 mRNA 
verexpression on patient survival ( P = 3.67e-3). OS was then analyzed
n colon cancer patients ( genomics.jefferson.edu/proggene ) for coordinate 
xpression of TROP2, CDH1, CTNNB1 transcripts by DNA microarray 
nalysis (160 cases, with 11 years of follow-up). Significant prognostic impact
n patient OS for single-determinant analysis was revealed for TROP2
HR = 1.96; P = 0.00058), with no significant impact of CDH1, CTNNB1
 Fig. 6 C). Remarkably, though, coordinate assessment of TROP2, CDH1,
TNNB1 provided much higher estimates of relative risk on disease outcome
nd patient survival than any individual parameter alone (HR = 3.85; P
 0.0042) ( Fig. 6 C), consistent with a coordinate impact of the Trop-2-driven
odule on cancer relapse. 
iscussion 
In this work we identified Trop-2 as a unique upregulated gene across
olon cancer metastasis models and showed for the first time that Trop-2
nduces ADAM10 activation for E-cadherin cleavage and inactivation. 
E-cadherin has a primary role in establishing cell-cell junctions and
aintaining normal tissue architecture, whilst β-catenin takes part to 
dherent junction complexes and mediates the interactions of E-cadherin 
ith the cytoskeleton by binding to α-catenin [46] . β-actin operates as
 scaffold for the assembly of a Ras/Raf/ERK/ezrin complex, which is
 key regulator of PI3K/Akt signaling through PI-phosphorylation. As a
onsequence, E-cadherin requires anchoring to β-actin for function, and 
908 Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer E. Guerra et al. Neoplasia Vol. 23, 
No. xxx 2021 
Fig. 6. Impact of the Trop-2/E-cadherin/ β-catenin module on colon cancer patient survival. ( A ) Colon cancer IHC staining over a series of cases from high 
(i) to low (iv) expression of Trop-2 (magnification 40x) ( left ). ( B ) ROC analysis was applied to obtain the Trop-2 positivity threshold according to the 0-1 
criterion. The optimal cut-off parameter for Trop-2 positive expression was 88% (Trop-2 high : score above the cut-off threshold; Trop-2 low score below the 
threshold). Kaplan-Meier analysis of overall survival (OS) according to Trop-2 expression levels: 57.1% of patients harboring Trop-2 hi . ( C ) DNA microarray 
data from colon cancer patients were pre-processed and meta-analyzed through the KMPlot database ( www.kmplot.com ). Kaplan-Meier (KM) curves showing 
the individual impact of TROP2, CTNNB1 and CDH1 transcript levels on overall survival (OS) are depicted on the left, while the impact of TROP2, CTNNB1 
and CDH1 coexpression is shown on the right. Vertical bars are shown for assessment at 3 and 5 years from diagnosis. 



















































































inhibition of tumor progression, through retention of β-catenin [46] . On
the opposite side, release of β-catenin leads to translocation to the nucleus,
and activation as a transcription factor on target genes, including those that
promote cell proliferation, differentiation, migration and angiogenesis [46] . 
In colon cancer experimental models, we revealed a gradient of metastatic
competence, with the lowest levels of nuclear β-catenin observed in the Trop-
2-nil non-metastatic KM12C colon cancer cells, higher levels measured in the
Trop-2-prone pro-metastatic KM12SM cells, and the highest levels reached
in the metastatic wtTrop-2 and cytoTrop-2 KM12SM cells. This paralleled
the ability of wtTrop-2 and cytoTrop-2 to induce ADAM10 cleavage of
E-cadherin and disanchoring from the cytoskeleton, which then led to a
corresponding loss of cell-cell aggregation. The transcriptional capacity of the
released β-catenin was demonstrated in β-catenin-RE-GFP reporter assays in
vitro . This was paralleled by massive induction of β-catenin transcriptional
target genes in wtTrop-2 and cytoTrop-2-driven metastases in vivo . No trace
of these changes was found in control metastasis, indicating that wtTrop-2
triggers a unique mechanism of metastatic dissemination. 
E-cadherin loss has been widely considered to be required for
EMT-dependent tissue invasion [47] . However, our findings showed no
transcriptional downregulation of the CDH1 gene in Trop-2-activated cells,
nor expression of EMT transcription factors that suppress the transcription
of epithelial differentiation markers. Instances of incomplete/graded EMT
have been recognized [ 25 , 31 , 47 , 48 ]. Our findings add a novel turn to these
scenarios, whereby Trop-2 induced E-cadherin cleavage and inactivation,
as mediated by ADAM10. Unsurprisingly, this associated to retention of
epithelial differentiation biomarkers, high levels of β-catenin and of β-
catenin transcriptional targets. Our findings thus appear to recapitulate
frequent surgical pathology assessments, that show inactivation/disarray of
E-cadherin in aggressive tumors [49] , for release of transcription-versed
β-catenin into the cytoplasm of cancer cells and association to tumor
progression [37] , in the apparent absence of loss of epithelial differentiation.
IHC analysis of distinct colon cancer case series showed that up to
88% of the tumors exhibited Trop-2 overexpression, and that overexpressed
Trop-2 was significantly associated with metastasis to lymph nodes. An
extended follow-up ( ≈400 months) of metastatic colon cancer patients,
showed that high Trop-2 expression correlated with poor OS, and with
fatal events in 57.1% of highly-expressing cases. Corresponding findings
were obtained by transcriptomic analysis of independent colon cancer
case series, where overexpression of Trop-2, β-catenin and E-cadherin
showed heavy impact on patient survival. Notably, this impact was not
matched by any of the risk factors taken individually, suggesting a
pivotal pathological role of the Trop-2-driven module on colon cancer
progression. Of note, the anti-Trop-2 mAb Sacituzumab govitecan-hziy
was shown to be effective in metastatic breast cancer patients [14-
17] and was granted accelerated FDA approval ( www.fda.gov/drugs/
drug-approvals-and-databases/drug-trial-snapshot-trodelvy). Our findings
provide ground for potential major relevance of Trop-2 as a target in
metastatic colon cancer. 
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